Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8258147 | 0.90 | CA2 (0.61) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL25670282 | 0.87 | CA2 (0.53) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL15116512 | 0.86 | CTSK (0.43) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL1915653 | 0.86 | CA2 (0.55) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL28486916 | 0.86 | CA2 (0.46) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL1915651 | 0.86 | CA2 (0.55) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL24360474 | 0.83 | CA2 (0.50) | CA2CA1CTSKMAPK1CTSS | |
| Potassium SCHEMBL30493921 | 0.83 | CA2 (0.66) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL20002265 | 0.83 | CA2 (0.50) | CA2CA1CTSKMAPK1CTSS | |
| SCHEMBL4458553 | 0.83 | CA2 (0.50) | CA2CA1CTSKMAPK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | CA2 2344/4885CA1 2797/4885CTSK 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.